Biosimilar Development
Navigate the complex landscape of biosimilar development with expert insights, regulatory guidance, and industry best practices. This category covers the full spectrum of the biosimilar lifecycle — from analytical characterization and comparability studies to clinical trial design, regulatory submissions, and post-approval strategy.
Whether you’re a scientist, regulatory affairs professional, or business strategist, our articles break down the scientific and regulatory intricacies of bringing biosimilars to market across major jurisdictions including the FDA, EMA, and beyond.
Topics covered include:
Structural and functional comparability assessments
Immunogenicity evaluation and risk mitigation
CMC (Chemistry, Manufacturing, and Controls) strategies
Regulatory pathways and dossier preparation
Interchangeability and substitution considerations
Market access, pricing, and commercialization trends
Stay ahead of evolving science, shifting regulations, and competitive dynamics in the growing biosimilar space.
